에이엠젠(Amgen Inc.)은 1980년에 설립되었으며 미국 캘리포니아주 서던 오크스(Thousand Oaks)에 본사를 두고, 획기적인 인간 의약품을 발견·개발·제조·전달하는 데 집중하는 글로벌 생명공학 리더입니다. 회사의 과학적 ...
암젠은 이물질과 cGMP 편차 같은 품질 관리 문제로 인해 특정 코를라노르 및 센시파 로트를 대상으로 전국 단위 리콜을 시작했습니다. 이는 미국 내 여러 제품 로트에 영향을 미칩니다. 암젠의 주가는 견조한 성과를 보였지만, 이번 리콜로 제조 통제에 대한 추가 점검이 도입되며 규제 당국의 관심을 끌 수 있습니다. 투자자들은 운영 리스크에 대한 통찰을 얻기 위해 회사의 개선(시정) 노력과 경영진의 코멘터리를 모니터링할 것이 권고됩니다.
암젠은 FDA가 약물 유발 간 손상으로 인해 타브네오스의 철회를 제안한 가운데, 해당 약과 관련해 중요한 7월 29일 FDA 데드라인에 직면해 있습니다. 이는 최근 연방 판사가 암젠의 엔브렐에 대한 콜로라도의 가격 상한을 차단해 상당한 매출을 보호한 판결 이후에 나온 소식입니다. 월가가 신중한 "보유(hold)" 등급을 유지하는 가운데, TIKR의 모델은 타브네오스 논란에도 불구하고 EPS 재가속을 예상하며 암젠 주식의 더 높은 밸류에이션을 전망합니다.
이 기사는 스테이트 스트리트 SPDR S&P 바이오테크 ETF(XBI)의 상세 프로필을 제공하며 배당금, 수익률, 주요 특징을 설명합니다. XBI가 미국 바이오테크 주식을 동일 가중으로 편입하는 데 중점을 두고, 운용 스타일, 비용 비율, 최근 성과 지표를 강조합니다. 또한 해당 펀드의 자산 배분, 지역별 노출, 주요 보유 종목에 대한 정보도 포함합니다.
구겐하임은 암젠(NASDAQ:AMGN)에 대한 목표 주가를 이전 $340에서 $343으로 올리며, 종가 대비 소폭 잠재 하방이 있을 수 있음에도 불구하고 "중립" 등급을 유지했습니다. 이번 조정은 EPS와 매출 추정치를 상회한 암젠의 견조한 분기 실적에 따른 것으로, 그 결과 FY2026 가이던스가 상향됐습니다. 분석가들의 암젠 전반에 대한 시각은 평균 "보유(Hold)" 등급과 함께 엇갈리는 가운데, 회사의 최근 재무 성과는 긍정적인 전망을 시사합니다.
Amgen Inc. (AMGN)은 상승(트렌딩) 주식으로 분류되며, 이에 따라 단기 실적에 영향을 미치는 요인을 점검할 필요가 있습니다. 이 기사는 실적 추정치의 수정, 예상 매출 성장, 애널리스트 기대치 대비 과거 성과를 분석합니다. Zacks Rank #3(보유)와 밸류에이션 부문 "C" 등급을 바탕으로, 분석에서는 Amgen이 단기적으로는 전반적인 시장과 유사한 흐름을 보일 수 있다고 시사합니다.
암젠은 이물질과 cGMP 편차 같은 품질 관리 문제로 인해 특정 코를라노르 및 센시파 로트를 대상으로 전국 단위 리콜을 시작했습니다. 이는 미국 내 여러 제품 로트에 영향을 미칩니다. 암젠의 주가는 견조한 성과를 보였지만, 이번 리콜로 제조 통제에 대한 추가 점검이 도입되며 규제 당국의 관심을 끌 수 있습니다. 투자자들은 운영 리스크에 대한 통찰을 얻기 위해 회사의 개선(시정) 노력과 경영진의 코멘터리를 모니터링할 것이 권고됩니다.
암젠은 FDA가 약물 유발 간 손상으로 인해 타브네오스의 철회를 제안한 가운데, 해당 약과 관련해 중요한 7월 29일 FDA 데드라인에 직면해 있습니다. 이는 최근 연방 판사가 암젠의 엔브렐에 대한 콜로라도의 가격 상한을 차단해 상당한 매출을 보호한 판결 이후에 나온 소식입니다. 월가가 신중한 "보유(hold)" 등급을 유지하는 가운데, TIKR의 모델은 타브네오스 논란에도 불구하고 EPS 재가속을 예상하며 암젠 주식의 더 높은 밸류에이션을 전망합니다.
이 기사는 스테이트 스트리트 SPDR S&P 바이오테크 ETF(XBI)의 상세 프로필을 제공하며 배당금, 수익률, 주요 특징을 설명합니다. XBI가 미국 바이오테크 주식을 동일 가중으로 편입하는 데 중점을 두고, 운용 스타일, 비용 비율, 최근 성과 지표를 강조합니다. 또한 해당 펀드의 자산 배분, 지역별 노출, 주요 보유 종목에 대한 정보도 포함합니다.
구겐하임은 암젠(NASDAQ:AMGN)에 대한 목표 주가를 이전 $340에서 $343으로 올리며, 종가 대비 소폭 잠재 하방이 있을 수 있음에도 불구하고 "중립" 등급을 유지했습니다. 이번 조정은 EPS와 매출 추정치를 상회한 암젠의 견조한 분기 실적에 따른 것으로, 그 결과 FY2026 가이던스가 상향됐습니다. 분석가들의 암젠 전반에 대한 시각은 평균 "보유(Hold)" 등급과 함께 엇갈리는 가운데, 회사의 최근 재무 성과는 긍정적인 전망을 시사합니다.
Amgen Inc. (AMGN)은 상승(트렌딩) 주식으로 분류되며, 이에 따라 단기 실적에 영향을 미치는 요인을 점검할 필요가 있습니다. 이 기사는 실적 추정치의 수정, 예상 매출 성장, 애널리스트 기대치 대비 과거 성과를 분석합니다. Zacks Rank #3(보유)와 밸류에이션 부문 "C" 등급을 바탕으로, 분석에서는 Amgen이 단기적으로는 전반적인 시장과 유사한 흐름을 보일 수 있다고 시사합니다.
Guggenheim은 Amgen Inc. (NASDAQ: AMGN)의 주가 목표가를 340달러에서 343달러로 올리며, 중립(Neutral) 등급을 유지했습니다. 이는 회사의 2026년 2분기(2분기) 실적 발표를 앞두고 나온 조치입니다. 이 회사는 일부 제품에서 예상보다 약한 스크립트(처방) 동향과 일부 제품에서의 더 강한 성과를 반영해 2분기 및 2026년 연간에 대한 매출과 EPS 추정치를 조정했습니다. 업데이트는 바이시밀러(바이오시밀러) 진입으로 인해 데노수맙 제품의 매출 침식이 가속되는 등 엇갈린 제품 성과를 반영하는 한편, Amgen 경영진과의 최근 논의 및 IQVIA 스크립트 동향 분석도 반영합니다.
BofA Securities는 Amgen Inc. (NASDAQ: AMGN)의 주가 목표가를 307달러에서 312달러로 올리면서, 중립(Neutral) 등급을 유지했습니다. 핵심 성장 프랜차이즈 전반에서의 강한 실행을 근거로 들었습니다. 2분기 예상 매출 93.8억 달러로 나타나는 비교적 완만한 단기 전망에도 불구하고, Amgen은 단기 실적 성장 대비 낮은 PER(주가수익비율) 때문에 저평가된 것으로 평가됩니다. 이 회사는 2026년에는 2027년의 주요 파이프라인 발표를 앞두고 실행에 집중할 것으로 예상하며, MariTide와 olpasiran을 포함한다고 설명합니다. 또한 희귀질환 치료제 Tavneos에 관해 최근에 있었던 활동도 언급했습니다.
Armata Pharmaceuticals는 복잡한 황색포도상구균 균혈증 치료제인 AP-SA02에 대한 최초 소아 연구 계획(iPSP)에 대해 FDA의 합의를 받았습니다. 이번 이정표는 향후 바이오의약품 허가 신청(Biologics License Application) 제출에 있어 중요하며, 성인과 동일한 적응증으로 최대 17세까지의 소아 환자로의 개발 확장도 가능하게 합니다. 소아 연구는 성인의 3상 안전성 및 유효성 데이터가 확보될 때까지 보류되며, 3상 연구는 2026년 말로 계획되어 있습니다.
BofA Securities has increased its price target for Amgen Inc. (NASDAQ:AMGN) to $312 from $307, while maintaining a Neutral rating, citing strong execution in its growth franchises. Despite the biotech giant trading above this target at $363.39, an InvestingPro tip suggests it appears undervalued given its low P/E ratio relative to near-term earnings growth. The firm’s revenue and EPS projections for Q2 are slightly below consensus, with a significant focus on pipeline readouts anticipated in 2027.
GSK's partner Hansoh Pharma has announced that its antibody-drug conjugate (ADC), risvutatug rezetecan (Ris-Rez), met all primary and key secondary endpoints in a Phase III trial for advanced or relapsed small-cell lung cancer (SCLC) in China. The trial showed significant improvements in overall survival and progression-free survival compared to standard chemotherapy, making it the first positive Phase III OS data for a B7-H3-targeted ADC. GSK, which holds exclusive license rights outside of Greater China, plans further global development,
J. Safra Sarasin Holding AG reduced its stake in Amgen Inc. by 15.5% in the first quarter, selling 38,033 shares and now owning 207,680 shares valued at $73,072,000. Despite this, several other institutional investors increased their holdings in Amgen, and the company reported strong financial results, beating analyst earnings estimates and providing a positive FY 2026 guidance. Analyst ratings for Amgen are mixed, with a consensus "Hold" rating and a target price of $355.73, and insider selling has also been noted.
Absher Wealth Management LLC reduced its stake in Amgen Inc. by 4.4% in the first quarter, now holding 74,920 shares valued at $26.36 million, making Amgen its 19th largest holding. Other institutional investors also adjusted their positions, with IFC Advisors LLC boosting holdings by 2.2% and Global Assets Advisory LLC by 6.9%. An insider, SVP Nancy A. Grygiel, sold 1,237 shares of Amgen stock in May, valued at over $400,000.
Immutep (ASX:IMM) shares surged 30% after releasing positive overall survival data from its INSIGHT-003 lung cancer study, offering renewed hope for its eftilagimod alfa treatment. This comes after the previous TACTI-004 trial was discontinued due to a futility analysis. The company plans to unveil more results soon and is investigating why the TACTI-004 trial failed to meet expectations.
Castleview Partners LLC reduced its stake in Amgen Inc. by 37.7% in the first quarter, now holding 7,860 shares valued at $2.77 million. Despite this, other hedge funds increased their positions, and Amgen reported strong Q1 results, exceeding EPS and revenue estimates. The stock currently holds a "Hold" rating from analysts, with an average price target of $355.73.
Ferguson Wellman Capital Management Inc. increased its stake in Amgen Inc. (NASDAQ:AMGN) by 1.7% during the first quarter, now holding 319,238 shares valued at $112.324 million. Other institutional investors have also adjusted their positions in Amgen, with 76.50% of the stock currently owned by institutional investors. An Amgen SVP recently sold 1,237 shares for over $400,000, reducing their stake by 15%, while analysts have issued various ratings for the stock, with a consensus "Hold" rating and an average target price of $355.73.
Cullinan Associates Inc. decreased its stake in Amgen Inc. by 18.1% in the first quarter, now holding 25,516 shares valued at approximately $8.98 million. Despite this reduction, Amgen reported strong quarterly results, with EPS of $5.15 and revenue of $8.62 billion,
Fifth Third Bancorp significantly increased its stake in Amgen Inc. by 57.2% in the first quarter, purchasing an additional 167,835 shares and growing its total holdings to 461,207 shares valued at $162.3 million. Amgen's stock traded essentially flat, while the company reported strong Q1 earnings, beating analyst estimates for both EPS and revenue. Analysts currently maintain a consensus "Hold" rating for Amgen with an average price target of $355.73.
Amgen Inc. (AMGN) maintains its profile as a large-cap biotechnology company with a diversified portfolio in inflammation, oncology, and cardiovascular care. The company's business model relies on marketed therapies, providing a more stable revenue base compared to smaller biotech firms focused on experimental assets. This strategic approach emphasizes operating execution and pricing power, making Amgen a defensive option for investors seeking biotechnology exposure without high binary clinical-event risk.
Candriam S.C.A. increased its stake in Amgen Inc. by 0.9% in the first quarter, now owning 395,351 shares worth $139.1 million. Other institutional investors like Vanguard Group Inc., State Street Corp, and Capital World Investors also significantly boosted their holdings in Amgen. The company's stock has shown recent price performance, and analysts have issued various ratings, with a consensus "Hold" and a price target of $355.73.
Conning Inc. has reduced its stake in Amgen Inc. by 5.4% in the first quarter, selling 5,475 shares but still holding 96,214 shares valued at $33.85 million. Despite Conning's reduction, institutional ownership of Amgen remains high at 76.5%, with several other firms increasing their positions. Amgen also surpassed quarterly expectations with strong EPS and revenue, maintaining an average "Hold" rating from analysts.
Argenx, a biotech company specializing in antibody-based treatments for autoimmune diseases, is positioned in the high-risk, high-reward segment of global biotech with a dual listing on Euronext Brussels and Nasdaq. The company's focus on precision medicine and long-term care for chronic autoimmune diseases aims to generate recurring revenue streams through its pipeline of antibody engineering programs. Investors monitor clinical trial outcomes, regulatory approvals, and commercialization strategies, balancing these risks with the potential for significant rewards from innovative therapies addressing unmet medical needs.
This article lists various Exchange Traded Funds (ETFs) that hold shares of Amgen Inc. stocks, providing details such as market value, weight of Amgen in the fund, issuer, management style, expense ratio, AUM, price change, and 3-year NAV total return. The ETFs cover a range of investment styles including total market, large cap, high dividend yield, and sector-specific focuses like health care and biotechnology. This information helps investors identify funds offering diversified exposure to Amgen Inc. while managing risk.
This article summarizes Veradermics' presentation at the Jefferies Global Healthcare Conference 2026, highlighting the significant market opportunity for a new hair loss treatment. The company's oral therapy, VDPHL01, showed positive Phase II/III clinical trial results with high patient satisfaction and a strong safety profile. Veradermics plans to strategically commercialize the product by targeting distinct patient segments and leveraging digital acquisition strategies, aiming to address the substantial unmet need in the hair loss market.
Munich Reinsurance Co Stock Corp in Munich significantly reduced its stake in Amgen Inc. by selling 2,916 shares, decreasing its position by 83.8% to 563 shares worth $198,000. This comes as other institutional investors like Vanguard Group Inc., State Street Corp, and Capital World Investors either increased their holdings or established new positions in Amgen. The article also notes recent insider selling by Amgen's SVP and provides financial details, recent earnings, and analyst ratings for the company.
Ibex Wealth Advisors has significantly increased its stake in Amgen Inc. by 51.3% in the first quarter, now holding 43,734 shares valued at $15.4 million. This move comes as Amgen reported stronger-than-expected quarterly earnings with an EPS of $5.15 and revenue of $8.62 billion. Despite a mixed outlook from analysts, with a consensus "Hold" rating and a price target of $355.73, several firms have recently raised their price targets for the biotechnology company.
Amgen Inc. (NASDAQ:AMGN) has received an average "Hold" rating from thirty brokerages, with an average 12-month price target of $355.73. The company recently reported strong quarterly results, exceeding EPS and revenue estimates, and reiterated its FY2026 EPS guidance. While insider selling by an SVP was noted, institutional investors showed mixed activity, with some increasing their stakes.
Mesoblast Limited announced strong Ryoncil net revenue, reaching US$36 million in Q4 FY26 and US$115 million for the full fiscal year, exceeding projections due to high U.S. pediatric demand. CEO Dr. Silviu Itescu confirmed the company's robust capital position, fueled by revenue growth and new financing, which will support strategic initiatives like label extensions and further product development. Ryoncil is the only FDA-approved treatment for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD), with development ongoing for additional inflammatory diseases and the rexlemestrocel-L platform for heart failure.
This page provides live quotes and charts for Amgen Inc. (AMGN) stock, showing its current price of $366.56 with a slight decrease of $1.54 (-0.42%). It also indicates that there are currently no analyst ratings or earnings information available for Amgen Inc. The article also contains extensive disclaimers about the risks of day trading and general investment advice.
Amgen Inc. (AMGN) stock decreased by 1.19% to $363.62 on Thursday, marking its second consecutive day of losses. Despite this decline, the stock outperformed the broader market, which saw the S&P 500 Index rise by 0.81% and the Dow Jones Industrial Average increase by 0.27% during the same trading session.
Precigen (PGEN) has been removed from several Russell indexes, which could impact its trading volumes and pricing despite strong recent stock performance. The company's stock is currently considered 55.3% undervalued by analysts, with a fair value estimate of $12.45, largely driven by the rapid uptake of its PAPZIMEOS treatment. However, its high P/B ratio of 98x compared to an industry average of 2.8x raises concerns about potential valuation risk, especially for a company that is still loss-making.
Artificial intelligence (AI) is transforming drug discovery by helping researchers analyze complex data, generate hypotheses, and identify patterns, but it is not a shortcut. Key challenges remain, including predicting drug behavior in the human body and ensuring safety, requiring progress to link insights across the entire lifecycle of a molecule. The future of AI in drug discovery hinges on high-quality data, biological understanding, and collaboration across scientific disciplines, ultimately aiming to accelerate the development of new medicines for patients.
This page provides news and articles related to the Roundhill GLP-1 & Weight Loss ETF (OZEM). It features current stock data for OZEM and highlights an article discussing two major drugmakers dominating the obesity market and how one fund invests in both. The page also includes other financial articles, primarily focused on personal finance topics like mortgage payments and pension planning.
Truist has raised its price target on Amgen (AMGN) to $340 from $327, citing expectations for a Q2 rebound in biotech, strong commercial franchises, and a robust catalyst calendar. This follows a previous price target raise by Mizuho analyst Salim Syed. However, Morgan Stanley recently lowered its price target to $333, maintaining an Equal Weight rating but noting potential benefits from broader market leadership and lower interest rates for the biotech sector.
The iShares S&P 500 Value ETF (IVE) has reached a new 52-week high, prompting investors to consider whether to sell. Despite the fund's current valuation being higher than its 5-year median, its diversification and broad participation in the rally suggest that "doing nothing" might be the most effective strategy. The article recommends holding unless the position has exceeded a planned allocation, and suggests using analytical tools to compare IVE against other ETFs for optimal performance.
This article examines investment options for capitalizing on the booming GLP-1 obesity drug market, dominated by Eli Lilly and Novo Nordisk. While the broad Health Care Select Sector SPDR Fund (XLV) offers diluted exposure, the specialized LeaderShares Dr. Bill Grace Global Obesity ETF (OZEM) provides more concentrated holdings in these key drugmakers. However, direct investment in companies like Eli Lilly has significantly outperformed both ETFs, highlighting trade-offs between diversification and focused growth.
X4 Pharmaceuticals, trading on Nasdaq as XFOR, is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for rare primary immunodeficiency and related disorders. Its strategy centers on niche medical needs and orphan drug designation, providing specialized treatments for conditions with limited options. The company's pipeline and clinical trial outcomes are critical for investors, as success in specific programs can significantly impact its valuation, particularly as it relies on external financing as a clinical-stage biotech.
The Myasthenia Gravis (MG) market is projected to grow significantly from USD 6 billion in 2025 to nearly USD 16 billion by 2036, driven by new therapies and increased awareness. Key market players like Argenx, Alexion, AstraZeneca, and Novartis are developing innovative treatments, including efgartigimod alfa-fcab (Vyvgart) and nipocalimab, which are expanding treatment options for various MG serotypes. The report highlights emerging therapies, market dynamics, epidemiological trends, and opportunities within the 7MM (United States, EU4, United Kingdom, and Japan).
The Myasthenia Gravis (MG) market is projected to grow significantly from USD 6 billion in 2025 to nearly USD 16 billion by 2036, driven by emerging therapies and increased awareness. Key market players like Argenx, Alexion, and UCB Biopharma are developing new treatments, including expanded indications for efgartigimod alfa-fcab (Vyvgart) and zilucoplan. The report highlights recent FDA approvals and promising clinical trial results for various therapies, focusing on advancements in addressing different MG serotypes and improving patient outcomes.
Torrent Pharmaceuticals is voluntarily recalling specific batches of its Semalix semaglutide injection pens. This action follows a product recall notification issued by its manufacturer, Dr. Reddy's Laboratories. The recall concerns select semaglutide pens, a drug used for diabetes treatment.
Sumitomo Mitsui Trust Group Inc. significantly reduced its stake in Amgen Inc. by 4.6% in the first quarter, selling over 74,000 shares. Despite this, other institutional investors increased their holdings, and overall hedge funds own 76.50% of the company. The article also details recent analyst ratings, Amgen's financial performance, and insider trading activity, noting a recent stock sale by SVP Nancy A. Grygiel.
Resona Asset Management Co. Ltd. increased its stake in Amgen Inc. by 2.1% in the first quarter, acquiring an additional 3,704 shares. This brings their total holding to 176,626 shares
Greenwood Capital Associates LLC significantly increased its stake in Amgen Inc. by 115.5% in the first quarter, now holding over 30,000 shares valued at $10.7 million. Amgen also reported strong first-quarter earnings, exceeding analyst expectations, and provided optimistic FY 2026 EPS guidance. Despite mixed analyst ratings and ongoing concerns about potential drug recalls and pricing risks, institutional investors continue to adjust their positions in the medical research company.
Amgen has seen a 12% stock gain in the last six months, outpacing the S&P 500's 7.7% return. The biotechnology company demonstrates strong long-term revenue growth and excellent free cash flow margins, indicating a robust operational performance. However, a declining return on invested capital suggests new investments are not yet yielding expected returns, which warrants careful consideration despite the company's overall positive attributes.
Amgen (AMGN) has kept pace with the market, gaining 12% in the last six months, slightly outperforming the S&P 500. The biotechnology company shows strong long-term revenue growth and excellent free cash flow margins, indicating a healthy financial state and ability to reinvest. However, a declining return on invested capital (ROIC) suggests that recent investments may not yet be yielding expected results, warranting careful consideration despite overall positive aspects.
RBC Capital has reiterated its Buy rating on Amgen (AMGN.US) and maintained its target price at $370. This indicates a continued positive outlook from the analyst firm on the biotechnology company's stock performance.
Moderna has settled a patent dispute with Arbutus Biopharma and Genevant Sciences concerning the lipid nanoparticle technology used in its COVID-19 vaccine, agreeing to a $950 million upfront payment. This settlement resolves multi-year litigation, removes legal uncertainty, and allows Moderna to focus on its broader mRNA pipeline. Investors should consider the impact of this payment on Moderna's financials and its high valuation signals.
Neurocrine Biosciences (NBIX) has returned 89.9% over the past five years, with its stock now appearing closer to fair value than a clear bargain. The company's P/E ratio is 26.8x, slightly above the biotech industry average, but close to its tailored fair P/E of 28.0x, indicating it's trading at a roughly fair earnings multiple. Future performance will depend on the durability of existing products and the successful execution of its pipeline, particularly without significant clinical or regulatory setbacks.
Brian Tyler, CEO of McKesson, shares his insights on leadership, the importance of AI in healthcare, and his strategies for success. He highlights McKesson's achievements in expanding patient support through oncology and biopharma platforms and discusses the qualities he seeks in leaders, such as curiosity, humility, and sound judgment. Tyler also touches on his personal habits, like daily exercise, and a favorite podcast, "Acquired," for business lessons.
This article compares two healthcare ETFs, Invesco Nasdaq Biotechnology ETF (IBBQ) and State Street SPDR S&P Pharmaceuticals ETF (XPH), to determine which is the better buy for investors. IBBQ offers a lower expense ratio, higher dividend yield, and broader diversification across 253 companies, while XPH has delivered higher 1-year total returns and focuses on 65 pharmaceutical companies with an equal-weighted approach. The analysis concludes that IBBQ is generally more suitable for long-term investors due to its lower cost and broader exposure, while XPH is a more targeted bet for those with specific conviction in the pharmaceutical sub-sector.
Oramed Pharmaceuticals is drawing investor attention due to its oral drug delivery platform, which aims to develop capsule-based alternatives to injectable biologic drugs. The Nasdaq-listed biotech focuses on clinical-stage development, with a notable project being an oral insulin capsule for diabetes. Investors are monitoring milestone events, regulatory feedback, and potential collaborations, as the company works to advance and monetize its oral drug delivery technology.
